Is Resmetirom currently on the market in China?

Resmetirom-Rezdiffra is a new treatment drug for non-alcoholic steatohepatitis (NASH). It has not been approved for marketing in China and has not been included in the medical insurance system. This means that domestic patients cannot obtain the drug through regular hospital channels or medical insurance reimbursement, and their use must rely on overseas legal channels or clinical trial research. Overseas, rismetirol is in the clinical development and regulatory approval stages, mainly targeting adult patients with moderate to severe NASH, especially those who have stage F2 to F3 liver fibrosis. Its treatment goal is not only to reduce liver lipid deposition, but also to improve liver function indicators and delay the progression of fibrosis, providing new drug management methods for patients with chronic metabolic liver disease.

Resmetirol is often used in conjunction with lifestyle intervention, including proper diet, weight control, and regular exercise. This comprehensive treatment strategy can enhance drug efficacy and improve the patient's overall metabolic status. Clinical studies indicate that medications alone may not be sufficient to completely reverse liver damage, so lifestyle improvements are an important component of NASH management. While patients are waiting for drug launches or clinical trial opportunities, they should pay attention to dietary structure adjustments and weight management to reduce liver fat accumulation and inflammation progression.

Although resmetirol has not yet been approved in China, its positive efficacy in international studies has attracted widespread attention. ForNASH patients, drug developers are working to evaluate its efficacy, safety and tolerability through long-term clinical trials, paving the way for future domestic marketing. For patients who wish to use this drug, participate in international multi-center clinical trials or obtain the drug through formal overseas channels, they still need to strictly abide by doctor's instructions, combined with regular liver function monitoring and metabolic assessment.

Reference materials:https://www.drugs.com/monograph/resmetirom.html